# Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT

> **NCT00246974** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 125 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT00246974
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2007-10
- **Final completion:** 2007-12
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2008-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00246974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00246974, "Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00246974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*